Drug data last refreshed 15h ago
NORITATE is a topical 1% metronidazole cream approved in 1997 for rosacea and other dermatologic and systemic infections. Metronidazole is a nitroimidazole antimicrobial whose mechanism of action in rosacea remains unknown, though it demonstrates broad activity against anaerobic bacteria and parasites. Topical application results in minimal systemic absorption (<1% of oral dosing).
Minimal commercial activity with only 1,454 Part D claims in 2023; limited team expansion likely given approaching loss of exclusivity.
Nitroimidazole Antimicrobial
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Worked on NORITATE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moNORITATE generates minimal career opportunity due to small market size ($3M Part D spend), approaching loss of exclusivity, and zero linked job postings. Career growth on this product is severely constrained.